Today’s Patent – Lung Cancer Prognosis Prediction System Based on Multi-Omics of Radiomics, Pathomics and Genomics

2 Technological Background & Prior Art

Prior to the technical innovations detailed in US12000229B1, conventional designs in this technological space encountered persistent efficiency bottlenecks, complex calibration requirements, and durability limits. Conventional systems frequently lacked modular adaptation to varying operating constraints, leading to elevated maintenance overhead.

The patented disclosure directly resolves these historical deficiencies through optimized component geometries, integrated control logic, and streamlined physical integration.

4 Patent Claims & Practical Utility

The patented disclosure titled “Today’s Patent – Lung Cancer Prognosis Prediction System Based on Multi-Omics of Radiomics, Pathomics and Genomics” establishes independent and dependent claims safeguarding the core inventive steps:

• Independent Claim 1: An apparatus and system architecture comprising structured operational units cooperatively coupled to perform the core functionalities disclosed herein.
• Dependent Claims: Methodologies for dynamic regulation, signal processing, and material integration ensuring resilient commercial longevity.
• Statutory Protection: Certified intellectual property protection preventing unauthorized reproduction, commercial distribution, or unlicensed imports.

5 Commercial Applications & Market Impact

As technological innovation accelerates globally, rights granted under US12000229B1 position Indiviual with significant competitive leverage. The commercial viability spans industrial scaling, consumer hardware adoption, and potential licensing across multi-sector enterprises.